Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
29 01 2019
Historique:
pubmed: 16 1 2019
medline: 23 3 2019
entrez: 16 1 2019
Statut: ppublish

Résumé

Influenza is a yearly threat to global public health. Rapid changes in influenza surface proteins resulting from antigenic drift and shift events make it difficult to readily identify antibodies with broadly neutralizing activity against different influenza subtypes with high frequency, specifically antibodies targeting the receptor binding domain (RBD) on influenza HA protein. We developed an optimized computational design method that is able to optimize an antibody for recognition of large panels of antigens. To demonstrate the utility of this multistate design method, we used it to redesign an antiinfluenza antibody against a large panel of more than 500 seasonal HA antigens of the H1 subtype. As a proof of concept, we tested this method on a variety of known antiinfluenza antibodies and identified those that could be improved computationally. We generated redesigned variants of antibody C05 to the HA RBD and experimentally characterized variants that exhibited improved breadth and affinity against our panel. C05 mutants exhibited improved affinity for three of the subtypes used in design by stabilizing the CDRH3 loop and creating favorable electrostatic interactions with the antigen. These mutants possess increased breadth and affinity of binding while maintaining high-affinity binding to existing targets, surpassing a major limitation up to this point.

Identifiants

pubmed: 30642961
pii: 1806004116
doi: 10.1073/pnas.1806004116
pmc: PMC6358683
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Hemagglutinin Glycoproteins, Influenza Virus 0

Banques de données

PDB
['6D0U']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1597-1602

Subventions

Organisme : NIH HHS
ID : S10 OD023680
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI117905
Pays : United States

Informations de copyright

Copyright © 2019 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Conflict of interest statement: J.E.C. has served as a consultant for Takeda Vaccines, Sanofi Pasteur, Pfizer, and Novavax; is on the scientific advisory boards of CompuVax, GigaGen, Meissa Vaccines, and PaxVax; and is the Founder of IDBiologics.

Références

Proteins. 2015 Aug;83(8):1385-406
pubmed: 25670500
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
J Pharm Sci. 2008 Apr;97(4):1414-26
pubmed: 17721938
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14216-21
pubmed: 21825125
Nat Commun. 2017 May 15;8:15371
pubmed: 28504265
Nature. 2012 Sep 27;489(7417):526-32
pubmed: 22982990
PLoS Comput Biol. 2009 Dec;5(12):e1000627
pubmed: 20041208
Nat Biotechnol. 2017 Jul;35(7):667-671
pubmed: 28604661
J Virol. 2011 Oct;85(20):10905-8
pubmed: 21849447
Science. 2011 Aug 12;333(6044):843-50
pubmed: 21737702
Proteins. 1992 Apr;12(4):345-64
pubmed: 1579569
Front Immunol. 2018 Mar 02;9:413
pubmed: 29545810
Biochemistry. 2016 Aug 30;55(34):4748-63
pubmed: 27490953
J Chem Theory Comput. 2017 Jun 13;13(6):3031-3048
pubmed: 28430426
PLoS Comput Biol. 2018 Apr 27;14(4):e1006112
pubmed: 29702641
PLoS Comput Biol. 2015 Jul 06;11(7):e1004300
pubmed: 26147100
PLoS Comput Biol. 2013 Apr;9(4):e1003045
pubmed: 23637590
J Clin Invest. 2015 Jun;125(6):2523-31
pubmed: 25985274
Proteins. 2014 May;82(5):771-84
pubmed: 24174277
Nat Struct Biol. 2003 Jan;10(1):45-52
pubmed: 12459719
Nucleic Acids Res. 2017 Jan 4;45(D1):D466-D474
pubmed: 27679478
Proteins. 2015 Apr;83(4):771-80
pubmed: 25524709
Nat Biotechnol. 2014 Feb;32(2):191-8
pubmed: 24463572
Nature. 2009 Apr 16;458(7240):859-64
pubmed: 19370028
Nat Commun. 2014 Apr 10;5:3614
pubmed: 24717798
Proteins. 2009 Jun;75(4):846-58
pubmed: 19194863
J Mol Biol. 2017 Aug 18;429(17):2694-2709
pubmed: 28648617
Science. 2011 May 13;332(6031):816-21
pubmed: 21566186

Auteurs

Alexander M Sevy (AM)

Chemical & Physical Biology Program, Vanderbilt University, Nashville, TN 37235.
Center for Structural Biology, Vanderbilt University, Nashville, TN 37235.
Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232.

Nicholas C Wu (NC)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037.

Iuliia M Gilchuk (IM)

Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232.

Erica H Parrish (EH)

Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232.

Sebastian Burger (S)

Department of Mathematics, University of Leipzig, 04109 Leipzig, Germany.

Dina Yousif (D)

Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232.

Marcus B M Nagel (MBM)

Center for Structural Biology, Vanderbilt University, Nashville, TN 37235.
Vanderbilt Mass Spectrometry Research Center and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232.

Kevin L Schey (KL)

Vanderbilt Mass Spectrometry Research Center and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232.

Ian A Wilson (IA)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037.
The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037.

James E Crowe (JE)

Chemical & Physical Biology Program, Vanderbilt University, Nashville, TN 37235; james.crowe@vanderbilt.edu jens.meiler@vanderbilt.edu.
Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232.
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232.

Jens Meiler (J)

Chemical & Physical Biology Program, Vanderbilt University, Nashville, TN 37235; james.crowe@vanderbilt.edu jens.meiler@vanderbilt.edu.
Center for Structural Biology, Vanderbilt University, Nashville, TN 37235.
Department of Chemistry, Vanderbilt University, Nashville, TN 37235.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH